EG01449 is a quinoline-based neuropilin-1 (NRP1) antagonist with a Kd of 0.6 µM. It competitively inhibits the binding of VEGFA to NRP1 with an IC50 of 362 nM, preventing VEGFA-induced pain by inhibiting NRP1-dependent signaling and reducing sodium currents in sensory neurons. EG01449 can cross the blood-brain barrier, allowing for targeted actions within the central nervous system, and is utilized in pain research.
Target:
VEGFR
* VAT and and shipping costs not included. Errors and price changes excepted
